

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Application No.

Filing Date:

First Named Inventor

Group Art Unit

Examiner Name

Attorney Docket No.

11-28-2000

Nakayama

99,569-A

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
		Number	Kind Code ² (if known)			
DR	1	5,986,056		LaVallie <i>et al.</i>	11-16-1999	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
DR	2	WO	00/09551	A1	Jacobs <i>et al.</i>	02-24-2000		

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
DR	3	CELESTE <i>et al.</i> , "Identification of Transforming Growth Factor Beta Family Members Present in Bone-Inductive Protein Purified from Bovine Bone," <i>Proc. Nat. Acad. Sci. USA</i> 87: 9843-47 (1990).	
	4	HOGAN, "Bone Morphogenetic Proteins: Multifunctional Regulators of Vertebrate Development," <i>Genes Dev.</i> 10:1580-94 (1996).	
	5	JONES <i>et al.</i> , "Signalling by TGF-Beta Family Members: Short-Range Effects of Xnr-2 and BMP-4 Contrast with the Long-Range Effects of Activin," <i>Curr. Biol.</i> 6:1468-75 (1996).	
	6	JONES <i>et al.</i> , "Establishment of a BMP-4 Morphogen Gradient by Long-Range Inhibition," <i>Dev. Biol.</i> 194:12-17 (1998).	
	7	PAPPANO <i>et al.</i> , "Coding Sequence and Expression Patterns of Mouse Chordin and Mapping of the Cognate Mouse chrd and Human CHRDL Genes," <i>Genomics</i> 52:236-39 (1998).	
	8	PICCOLO <i>et al.</i> , "Dorsoventral Patterning in Xenopus: Inhibition of Ventral Signals by Direct Binding of Chordin to BMP-4," <i>Cell</i> 86:589-98 (1996).	
DR	9	WOZNEY <i>et al.</i> , "Novel Regulators of Bone Formation: Molecular Clones and Activities," <i>Science</i> 242:1528-34 (1988).	

Examiner
Signature

Daniel Rome

Date

Considered

3/18/3


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

RECEIVED

FILE COPY
JUN 25 1999
TECHNICAL CENTER 1600/2900



FILE COPY

Substitute for form 1449A/PTO				Complete if Known	
<p align="center">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p align="center">(use as many sheets as necessary)</p>				Application No.	09/724,915
				Filing Date:	November 28, 2000
				First Named Inventor	Nakayama et al.
				Group Art Unit	1635
				Examiner Name	
Sheet	1	of	2	Attorney Docket No.	99,569-A

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
AR	10	WO	99/57132 ✓	A	Genetics Inst.	11-11-99		
	11	WO	98/40483 ✓	A	Human Genome Sciences Inc.	9-17-98		
	12	WO	99/31236 ✓	A	Bougueleret Lydie; Genset SA	6-24-99		
AR	13	WO	00/09551 ✓	A	Genetics Inst.	2-24-00		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

Donald Romeo 3/18/13

Substitute for form 1449A/PTO SEP 17 2001 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application No.	09/724,915		
		Filing Date:	November 28, 2000		
		First Named Inventor	Nakayama et al.		
		Group Art Unit	1635		
Examiner Name					
Sheet	2	of	2	Attorney Docket No.	99-899-A

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	14	Database EMBL 'Online' PEARCE, A. Human DNA sequence from clone 141HS on chromosome Xq22. Contains parts of a novel Chordin Like protein with Von Willebrand factor type C domains. Contains ESTs, STSs and GSSs. NO DATE
	15	Database EMBL 'Online' COFFINE, C.C. et al. "Mus musculus neuralin mRNA, complete cds" NO DATE
4R	16	NAKAYAMA Naoki et al. "A Novel chordin-like protein inhibitor for bone morphogenetic proteins expressed preferentially in mesenchymal cell lineages." <u>Developmental Biology</u> 232: 372-387(2001)

Examiner Signature	<i>Donald Roney</i>	Date Considered	3/15/03
--------------------	---------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231